Enosi Therapeutics is a drug research and development company focused on providing industry-leading therapeutics for autoimmune diseases and cancer. The company was founded by world-renowned scientists Professor Sir Marc Feldmann, who discovered anti-tumor necrosis factor (anti-TNF) therapy as an effective treatment for rheumatoid arthritis and other autoimmune diseases ( Lasker Award, 2003 ); and Dr. H. Michael Shepard, whose research in humanized antibodies created the first monoclonal antibody therapy targeting cancer oncogene encoded-proteins ( Lasker award, 2019). Enosi Therapeutics combines Feldmann and Shepard’s expertise in cancer and autoimmune diseases with Executive Chairman Dr. James N. Woody’s unique combination of medical, scientific and management expertise to expand therapeutic options. To learn more about Enosi Therapeutics, visit www.enositherapeutics.com.
